Company Biosynex

Equities

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Sector Diagnostic & Testing Substances

Real-time Euronext Paris Other stock markets 12:41:40 03/05/2024 BST			5-day change	1st Jan Change
4.2 ^EUR	-0.47%		-20.75%	-49.70%

04-30	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-29	Biosynex: agreement for ProciseDx in North America	CF

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas:

- manufacturing of diagnosis tests for own account;

- sale of diagnosis tests supplied by other manufacturers of semi-finished products;

- research and development services for third party;

- sale of licenses;

- sale of biological reagents.

At the end of 2022, the group had one production site located in France.

France accounts for 61.1% of net sales.

Number of employees: 551

EUR in Million	2021	Weight	2022	Weight	Delta
Professionals 61.5 %	266	69.6 %	121	61.5 %	-54.58%
General Public 38.5 %	116	30.4 %	76	38.5 %	-35.00%

EUR in Million	2021	Weight	2022	Weight	Delta
France 61.1 %	194	50.6 %	120	61.1 %	-37.95%
International 38.9 %	189	49.4 %	76	38.9 %	-59.58%

Managers	Title	Age	Since
Thomas Lamy FOU	Founder	-	14/03/05
Larry Abensur CEO	Chief Executive Officer	69	14/03/05
Thierry Paper FOU	Founder	60	14/03/05
Elie Fraenckel DFI	Director of Finance/CFO	-	31/10/12
Oren Bitton SAM	Sales & Marketing	-	31/12/10

Members of the board	Title	Age	Since
Thierry Paper FOU	Founder	60	14/03/05
Thomas Lamy FOU	Founder	-	14/03/05
Larry Abensur CEO	Chief Executive Officer	69	14/03/05
Elie Fraenckel DFI	Director of Finance/CFO	-	31/10/12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,252,580	4,042,977 ( 39.43 %)	256,226 ( 2.499 %)	39.43 %

Name	Equities	%	Valuation
Larry Abensur 41.16 %	4,429,309	41.16 %	23 M €
Thomas Lamy 10.81 %	1,162,980	10.81 %	6 M €
Thierry Paper 3.624 %	389,988	3.624 %	2 M €
BIOSYNEX 0.9940 %	106,966	0.9940 %	556 245 €
Talence Gestion SAS 0.4089 %	44,000	0.4089 %	228 809 €
Meeschaert Asset Management SA 0.3811 %	41,006	0.3811 %	213 239 €
Lyxor International Asset Management SAS 0.0952 %	10,244	0.0952 %	53 271 €
EdgeHill Partners 0.0548 %	5,900	0.0548 %	30 681 €
La Française Inflection Point SASU 0.0353 %	3,797	0.0353 %	19 745 €
Sunny Asset Management SA 0.000000 %	0	0.000000 %	- €

Name	Equities	%	Valuation
BIOSYNEX 0.99%	106,966	0.99%	556,245 $

Biosynex SA

22, boulevard Sebastien Brant

67400, Illkirch-Graffenstaden

+33 3 88 78 78 87

http://www.biosynex.com

Name	Category and Sector
THERADIAG	Medical Specialties
Biosynex Swiss SA

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOSYNEX	-49.70%	48.58M
BIOMÉRIEUX	-0.60%	12.5B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.67B
LANTHEUS HOLDINGS, INC.	+26.10%	5.36B
DIASORIN S.P.A.	+0.21%	5.26B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.57B
10X GENOMICS, INC.	-53.02%	3.15B
ANDON HEALTH CO., LTD.	+6.42%	2.59B
VITROLIFE AB	-10.63%	2.06B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-8.29%	1.79B

Diagnostic & Testing Substances